Pannex Therapeutics Inc. has divulged pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of neuropathic pain and opioid dependency.
The σ2 receptor (σ2R) has been recently identified as transmembrane protein 97 (TMEM97), and ligands of σ2R/TMEM97 have previously shown the ability to alleviate mechanical hypersensitivity in mouse models of neuropathic pain.
All treatment groups in Vertex Pharmaceuticals Inc.’s phase II study of the non-opioid VX-548 showed meaningful reductions in pain from baseline in treating diabetic peripheral neuropathy (DPN), pointing the company toward pivotal phase III studies and prompting analysts to applaud enthusiastically.
Bsense Bio Therapeutics Ltd. has nominated BSEN-760, a dual Kv7.2/3 and TRPV1 ion channel modulator, as a clinical candidate for the treatment of chronic pain.
Hangzhou Bio Sincerity Pharmaceutical Technology Co. Ltd. has identified histamine H3 receptor antagonists reported to be useful for the treatment of pain, attention deficit hyperactivity disorder, schizophrenia, epilepsy, sleep disorders, obesity, eating disorder, neuropathic pain and itching.
Artelo Biosciences Inc. has completed a pre-IND meeting with the FDA regarding the manufacturing, preclinical and clinical development plan for ART-26.12.
Researchers from China Pharmaceutical University and affiliated organizations have reported the discovery and preclinical evaluation of a novel bromodomain and extra-terminal (BET) inhibitor, DDO-8926, being developed for the management of neuropathic pain.
Researchers from Universita degli Studi di Pavia and affiliated organizations have presented the discovery of a novel sigma-1 receptor (S1R) antagonist, RC-752, being developed as an antinociceptive agent for the treatment of neuropathic pain.
After almost 30 years in business, Sangamo Therapeutics Inc. is finally nearing a BLA filing for one of its programs. But the company, wounded by the recent loss of alliances with Biogen Inc. and Novartis AG, is also running out of cash and investor interest – and it badly needs a new deal to stay afloat.
Researchers at Mossakowski Medical Research Centre at the Polish Academy of Sciences (PAS) and The University of Warsaw have divulged peptides reported to be useful for the treatment of pain.